Novel benzo[D][1,3]-dioxol derivatives

A compound selected from any one of:

• or a salt thereof;
• or a prodrug or a salt of a prodrug thereof;
• or a hydrate, solvate or polymorph thereof;
• wherein all hydrogen atoms and all carbon atoms are present at their natural isotopic abundance.

A mixture consisting essentially of:

• a. a compound of formula I or a salt thereof;
• or a prodrug, or a salt of a prodrug thereof;
• or a hydrate, solvate, or polymorph thereof;
• and
• b. lighter isotopologues of said compound of formula I or said prodrug, or said salt of said prodrug;
• or said hydrate, solvate, or polymorph thereof;
• wherein at least 50% of said mixture is said compound of formula I.

A mixture consisting essentially of:

• a. a compound of formula I or a salt thereof;
• or a or a prodrug, or a salt of a prodrug thereof;
• or a hydrate, solvate, or polymorph thereof;
• and
• b. lighter isotopologues of said compound of formula I, said prodrug, said salt of said prodrug thereof;
• or said hydrate, solvate, or polymorph thereof;
• wherein at least 50% of the compounds in said mixture comprise an isotope at each position occupied by an isotope in the compound of formula I.

An article of manufacture comprising separate dosage forms of a composition comprising a compound of formula I, or a pharmaceutically acceptable salt thereof;

• or a prodrug, or a pharmaceutically acceptable salt of a prodrug thereof;
• or a hydrate, solvate, or polymorph thereof;
• and an acceptable carrier;
• and a second therapeutic agent, wherein both dosage forms are in a single container.

A method of inhibiting the uptake of serotonin in a subject comprising the step of administering to said subject a composition comprising an effective amount of a compound of formula I;

• or a pharmaceutically acceptable salt thereof;
• or a prodrug, or a pharmaceutically acceptable salt of a prodrug thereof;
• or a hydrate, solvate, or polymorph thereof;
• and a pharmaceutically acceptable carrier.

A method of treating a human or non-human subject suffering from or susceptible to depression, obsessive-compulsive disorder, generalized anxiety, post-traumatic stress, major depression, panic disorder, social phobia, premenstrual syndrome, cardiac disorders, non-cardiac chest pain;

• smoking to cause cessation or prevent relapses;
• reducing platelet activation states, alcoholism and alcohol dependence;
• psychiatric syndromes including anger, rejection sensitivity, and lack of mental of physical energy;
• late luteal phase dysphoric disorder, premature ejaculation, senile dementia, obesity, Parkinson's disease, canine affective aggression, cancer cell growth, osteoporosis, dermatological diseases or disorders such as hyperproliferative or inflammatory skin diseases, or premature female orgasm;
• said method comprising the step of administering to said subject a composition comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof;
• or a prodrug, or a pharmaceutically acceptable salt of a prodrug thereof;
• or a hydrate, solvate, or polymorph thereof;
• and an acceptable carrier.

A method of determining the concentration of Compound 1 in a biological sample comprising the steps of:

• a. adding a known concentration of a compound of formula I, or a salt thereof, to a biological sample;
• b. subjecting said biological sample to a measuring device that distinguishes Compound 1 from said compound of formula I;
• c. calibrating said measuring device to correlate the detected quantity of said compound of formula I with the known concentration of said compound of formula I added to said biological sample;
• and
• d. determining the concentration of Compound 1 in said biological sample by comparing the detected quantity of Compound 1 with the detected quantity and known concentration of said compound of formula I.

A compound of formula II

• wherein:
• D is deuterium;
• Y1 is independently selected from hydrogen or deuterium;
• each carbon atom is independently optionally replaced by 13C;
• and
• each hydrogen atom is independently optionally replaced by deuterium.

A compound of formula III

• wherein:
• D is deuterium;
• each of Y1-3 is independently selected from hydrogen or deuterium;
• W is a removable N-protecting group;
• each carbon atom is independently optionally replaced by 13C;
• and
• each hydrogen atom is independently optionally replaced by deuterium.